Weakly acidic refluxes have a major role in the pathogenesis of proton pump inhibitor-resistant reflux oesophagitis

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 5, 2011, Pages 601-606

  Frazzoni, M ^a   Conigliaro, R ^a   Melotti, G ^a  

^a Nuovo Ospedale S Agostino   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG MEGADOSE; ESOPHAGUS MANOMETRY; FEMALE; HEARTBURN; HUMAN; MALE; MONITORING; PATHOGENESIS; PH MEASUREMENT; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; STOMACH ACID;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG RESISTANCE; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; YOUNG ADULT;

EID: 79251471451     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04550.x     Document Type: Article

References (29)

1. DeVault KR, Castell DO,. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 190-200.
2. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80.
3. Frazzoni M, De Micheli E, Savarino V,. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. Aliment Pharmacol Ther 2003; 18: 1091-8.
4. Vakil N, van Zanten SV, Kahrilas P, the Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
5. Kahrilas PJ, Shaheen NJ, Vaezi MF,. American Gastroenterological Association Institute Technical Review on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1392-413.
6. Fass R, Sifrim D,. Management of heartburn not responding to proton pump inhibitors. Gut 2009; 58: 295-309.
7. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006; 55: 1398-402.
8. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006; 101: 1956-63.
9. Frazzoni M, Conigliaro R, Melotti G,. Reflux parameters as modified by laparoscopic fundoplication in 40 patients with heartburn/regurgitation persisting despite PPI therapy. A study using impedance-pH monitoring. Dig Dis Sci 2010 [Epub ahead of print].
10. Ahlawat SK, Mohi-Ud-Din R, Williams DC, et al. A prospective study of gastric acid analysis and esophageal acid exposure in patients with gastroesophageal reflux refractory to medical therapy. Dig Dis Sci 2005; 50: 2019-24.
11. Poh CH, Gasiorowska A, Navarro-Rodriguez T, et al. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc 2010; 71: 21-34.
12. Sifrim D, Castell D, Dent J, et al. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004; 53: 1024-31.
13. Frazzoni M, Savarino E, Manno M, et al. Reflux patterns in patients with short segment Barrett's oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy. Aliment Pharmacol Ther 2009; 30: 508-15.
14. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
15. Holloway RH, Dent J, Narielvala F, et al. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996; 38: 649-54.
16. Katz PO, Ginsberg GG, Hoyle PE, et al. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2007; 25: 617-28.
17. Katz PO, Johnson DA, Levine D, et al. A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing? Aliment Pharmacol Ther 2010; 32: 443-7.
18. Roman S, Serraj I, Damon H, et al. Correlation between gastric pH and gastro-oesophageal reflux contents: ambulatory pH-impedance monitoring results. Neurogastroenterol Motil 2007; 19: 562-8.
19. Winkelstein A,. Peptic esophagitis (a new clinical entity). JAMA 1935; 185: 906-9.
20. Roberts NB,. Review article: human pepsins-their multiplicity, function and role in reflux disease. Aliment Pharmacol Ther 2006; 24 (Suppl. 2): 2-9.
21. Tsoukali E, Sifrim D,. The role of weakly acidic reflux in proton pump inhibitor failure, has dust settled? J Neurogastroenterol Motil 2010; 16: 258-64.
22. Becker V, Bajbouj M, Waller K, et al. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors-a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther 2007; 26: 1355-60.
23. Spechler JS,. Surgery for gastroesophageal reflux disease: esophageal impedance to progress? Clin Gastroenterol Hepatol 2009; 7: 1264-5.
24. Frazzoni M, Manno M, De Micheli E, et al. Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease. Spectrum disease or distinct phenotypic presentations? Dig Liver Dis 2006; 38: 643-8.
25. Frazzoni M, De Micheli E, Grisendi A, et al. Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression. Aliment Pharmacol Ther 2002; 16: 881-6.
26. Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultaneous impedance and pH-monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol 2004; 99: 1037-43.
27. Zerbib F, Bruley Des Varannes S, Roman S, et al. Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects. Aliment Pharmacol Ther 2005; 22: 1011-21.
28. Zentilin P, Iiritano E, Dulbecco P, et al. Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a Mediterranean diet. Dig Liver Dis 2006; 38: 226-32.
29. Hila A, Agrawal A, Castell DO,. Combined multichannel intraluminal impedance and pH esophageal testing compared to pH alone for diagnosing both acid and weakly acidic gastroesophageal reflux. Clin Gastroenterol Hepatol 2007; 5: 172-7.